Novo Nordisk’s Stock Takes a Hit Despite Weight Loss Drug Success

Novo Nordisk A/S NVO has been a leader in the weight loss drug market, but its stock faces significant declines that are raising eyebrows among investors.

Over the past year, shares have dropped 44.14%. They are down 17.4% year-to-date and saw a sharp decline of 19.27% in the last month alone.

The stock recently hit a 52-week low of $72.15, a stark contrast to its high of $148.15.

Stock Performance: A Bearish Trend

Chart created using Benzinga Pro

The stock is firmly entrenched in bearish territory, trading below its eight, 20, and 50-day exponential moving averages. This trend is indicative of persistent selling pressure.

The eight-day simple moving average (SMA) sits at $77.11, while the 20-day and 50-day SMAs are at $81.23 and $82.94, respectively, all signaling bearish momentum. Meanwhile, the 200-day SMA of $111.72 highlights the extent of this downturn.

Additionally, the MACD (moving average convergence/divergence) stands at a negative 3.04, and the RSI (relative strength index) measures 32.37, pointing to further potential declines.

Read also: If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

New Obesity Drug Acquisition: Timely or Too Late?

Novo Nordisk recently made headlines with its $2 billion deal to acquire rights to a Chinese obesity drug from United Laboratories International, but investors remain skeptical.

This treatment, known as UBT251, aims to compete with Eli Lilly & Co‘s LLY ‘Triple G’ obesity drug, retatrutide, which has already demonstrated promising results in weight loss, as reported by CNBC.

However, UBT251 is still in early-stage trials, raising concerns that Lilly’s product may enter the market first, leaving Novo Nordisk to play catch-up.

Challenges Ahead for Novo Nordisk

The challenges facing Novo Nordisk’s weight loss portfolio are mounting. Technical indicators suggest a continued bearish trend, and increasing competition raises doubts about the firm’s ability to maintain its market dominance.

As investors reflect on the recent drug acquisition, those betting on Novo Nordisk may find themselves needing more than just a new treatment to reverse the stock’s current downward trajectory. For the time being, the stock’s trend continues to move south.

Read Next:

Image: Shutterstock